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l?esu/ts:All investigators were sent a questionnaire concerning vital status
and heart transplantation for each patient 3 years after inclusion in the MDC
trial. Data regarding survival and heart transplantation were obtained in 318
of 383 patients. During the MDC-trial there were 44 deaths (21 placebo and
23 metoprolol). During the 3-year follow-up there were another 27 endpoints
in the patients originally receiving placebo (15 transplantations, 12 deaths),
and 17endpointa in the patients originally on metoprolol (13 transplantations,
4deaths). Transplantation-frw survival was 108 of 135 in the placebo group,
and 122 of 139 in the metoprolol group.
Corrchrs/on.’Although many patients received open treatment with beta-
blockade after the double blind phase of the study, the original trend toward
improved transplantation-free survival was maintained 3 years,after inclusion
In the study. Thus, beta-blockade treatment may induce beneficial effects on
myocardlal recovety that postpone future deterioration.
u ,at,en,8”996-55 Tolerability of Carvediioi Initiation in Heart Faiiure
M.B. Fowler, W.S. Colucci, M.R. Brlstow, M. Packer, E.M. Gilbert,
J.N. Cohn, B. WU,J.Z. Hu, M.A. Lukes, S. Kubo, R. Hershberger,
S. Gottlieb, 1.Pina, for the US Carvedllol Heart Failure Study Group.
Stanford Univerai~, Palo Alto, CA, USA
Instituting p-blockade in heatt failure patients (pts) can be associated with
worsening clinical status orother signs of intolerance. Carvadilol (C), combin-
ing nonselective p-and m+blockade with antioxidant effects, showed benefi-
cial effects on clinioal status, survival and morbidity in the US Carvedilol Heart
Failure Trials Program (NYHA II-IV pts with EF < 35% receiving digoxin, di-
uretics ancflor ACEI). We examined the study population retrospectively as
to the incidence of tolerating initiation. Open challenge”wlth C (mean 14 + 5
days) was followed by Minded (C or placebo) titration to target doses (TD) of
6.25 to 50 mg tWiGedaily.
Results: Initial C dose was 6.25 mg in 97% of 1197 pts challenged; 3%
began at, and 7% at some point received 3.125 mg bid during initiation.
Challenge withdrawals for safety were 5% (worsening CHF 2%, dizziness
1.1%, bradycardia 0.2Y0, death 0.57., other event 1.2%). During blinded
titration (C, 696: placebc, 398), 7SY. and 81% reached target dose, with
2.4Y0and 1.1% withdrawn for adverse event, respectively.Reducing diuretic
dose occurred in 8% of C pts but only 3% of pts on placebo. The incidence of
increasing diuretic or changing ACE dose, or mean up-titration days (19.3)
did not differ between C and placebo.
Conclusion: Target carvedilol dose can be successfully reached in most
heart failure pts. Adjustment of other medication, especially decreasing di-
uretic, may be needed in some patients.
D99656 Moxonidine improvea Heart Rete Variability inPatienta With Heart Faiiure
S.Juul-M611er,K. Swedbarg, K. Dickstein, J. McNay. Ma/mo University
Hospital, Malmo, Sweden
Reduced heart rate variability (HRV) reflects autonomic abnormalities and
carries a negative prognosis in heart failure (HF). Intervention with digitalis,
ACE inhibitora, beta blw”kera, and exercise training improves morbidity and
HRV in patients with HF. 96 patients with NYHA II-HI HF and EF-less than
40% on standard treatment were randomized to receive placebo (P) or
moxonidine (M) 0.1, 0.2 or 0.3 mg bid for three months in a multicenter,
double-blind study. 24 hour Helter ECGS were recorded at pretreatment
baseline and 11weeks.
Average changes were:
Doea,mgbid P 0.1 0.2 0.3
N* 19 22 28 t9
A 24 hr HR**, bpm 1 –1.6 –2.1 –3.6
A SDR-R***,ms 2, 2 10 tz
A PNE**”*,p~mi 185 -32 –41 –48
*Complaterewith NSRwithoutpacemaker;“*HR= heartrate;***SDR-R=atanrtardrJe-
vlatkmof5 minepochsofR-Rintervals;****pNE= ~lasmanorepinephrine
There were correlations between dosage of M and: decrease in HR (P=
0.0S),increase indaytifne SD R-R (P c 0.04) and decrease in PNE (P < 0.01).
We conclude that the increase in HRV and decrease in HR are consistent
with sympathetic inhibition confirmed by reduction in PNE. Moxonidine has
potential therapeutic value due to improvement in autonomic abnormalities
of HF.
m EfiWtSOfCOmbine& Therap~with*CElnhibition
and Angiotenain-il ATI Receptor Biockade in
Moderate Heart Faiiure
M. Tanimura, S. Shevlyagin, H. Shimoyama, S. Goldstein, H.N. Sabbah.
Henry Ford HeWand Vascu/arhrstitute Detroit, M/, USA
Long-term therapy with the ACE inhibitor enalaprii (ENA) was shown to at-
tenuate the progression of LVdysfunction in dogs with moderate heart failure
(HF). In the present study we determined whether combined therapy with
ENA and MK996, an angiotensin-11ATi receptor blocker, is more effective
in improving LV function and chamber remodeling than ENA alone. Stud-
ies were performed in 20 dogs with moderate HF (LV ejection fraction, EF =
35%-400A)produced by intracoronaty mlcroembcdlzations.Seven dogs were
treated for 3 months with ENA (10 mg Bid), 6 with ENA (10 mg Bid) plus
MK996 (5 mg Bid), and 7 were untreated (CON). In all dogs, mean aonic
pressure (MAP), LV EF,end-diastolic (EDV) and end-systolic (ESV) volumes
were measured before and after 3 months of therapy and the change (A) for
each parameter was calculated.
CON ENA ENA+ MK996
A MAP(mmHg) 14+6 -4 * 7 -24 k 7’
A LVEF(%) –10+ 1 3+3* 1l 1“
A LVEDV(ml) 16+3 4 *2* -1 *I*
A LVESV(ml) 18+3 1 * 3“ –1 l 1“
*P <0.01 VS.CON
Despite a marked reduction in MAP, combined therapy with ENA and
MK996 was similar to ENA alone in its ability to prevent the progressive da-
ciinein EFand the increase in EDV and ESV seen in CON dogs. Cone/us/on:
In dogs with moderate HF,combining ATI receptor blockade therapy to ACE
inhibition does not improve LVfunction and remodeling beyond that accrued
by ACE inhibition alone.
1996-701 Differen.esBeWeenReapOn*e*t~~ei~~iPinein
Heart Faiiure With and Without Coronary Disease:
V-HeFT iii
J.N. Cohn, T. Germanson, S. Ziesche, for the V-HeFT Study Group.
Minneapolis, MN, USA
Recent data have suggested the possibility of a differential therapeutic re-
sponse in heart failure due to corona~ disease (CAD), and non-ischemic
cardiomyopathy (non-CAD). The V-HeFT Ill data base was examined to
compare the response to the calcium antagonist felodipine 5 mg b.i.d. in
these populations.
Baseline observations:
CAD NON-CAD
246 204
lge (years) 64.5 61 .9”
Race (% white) 82 62*
Hypertensionhistoty(“A) 44 59*
Bloodpressure(S/D mmHg) 121i73 123r75
Heart rate (beattimin) 74.0 75.7
LV EjectionFraction(EF) (“A) 28.1 31 .5”
Exerciasduration(rein) 9,4 9.6
Plasma norepinephrine(pgiml) 508 512
Plasme strialpeptide (p@ml) 122 125
Ventriculartachycardia(%) 60 62
EF increased similarly at3months in responseto felodipine in both groups
(CAD, +1.6; non-CAD, +2.7) vs. placebo (CAD, +0.4, non-CAD, -0.6). There
was a trend for a more favorable response to felodipine at 12 months in non-
CAD than in CAD groups in exercise tolerance (+0.6 vs Orein) and plasma
norepinephrine (–10 p@mlvs. +57 p~ml) despite a similar incidence of new
ventricular tachycardia and no difference in the effect of F on mortality.
Therefore, patients with CAD were older and had a lower EF than non-
CAD heart failure patients. Felodipine exerted a somewhat greater effect on
non-motality end-points in the non-CAD group, but the effects on EF and
motiality were similar.
m BenefiCieiHemOdYnami.~~e.tsofA.u~e
inauiin-Like Growth Factor-1in Patients With
Chronic Heart Faiiure
G. Sutsch, M. Donath, X.-W. Yan, H.-P. Brunner, F. Follath, E.R. Froasch,
W. Kiowski. Cardiology and Endocrinolog~ University Hoapital, Ziirich,
Switzerland
Insulin-1ikegrowth factor-1(IGF) enhances myofibrillar development in vitro
